BC Extra | Jul 25, 2019
Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

Janssen’s ponesimod tops Aubagio in Phase III  The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it plans to submit NDAs to FDA and EMA this year after reporting ponesimod met the primary endpoint...
BC Extra | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data  Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BC Extra | May 2, 2019
Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

Biogen's ALS candidate reduces SOD1 protein levels in CSF  Biogen Inc. (NASDAQ:BIIB) will present on May 7 at the American Academy of Neurology meeting the interim Phase I/II data of tofersen that had prompted it...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Week In Review | Nov 9, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
BC Extra | Nov 5, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
BC Innovations | Aug 22, 2017
Distillery Therapeutics

Cancer

INDICATION: Cancer Patient sample and mouse studies suggest inhibiting NOX4 could help treat cancer. In samples from patients with squamous cell carcinoma of the head and neck (SCCHN), esophageal cancer, colorectal cancer, breast cancer or...
BC Extra | Aug 8, 2017
Preclinical News

Researchers suggest inhibiting NOX4 could treat cancer

In a paper published in the Journal of the National Cancer Institute , researchers at the University of Southampton showed that inhibiting NADPH oxidase 4 (NOX4) in cancer-associated fibroblasts can abrogate the tumor-promoting function of these...
BC Week In Review | Jul 3, 2017
Clinical News

Genkyotex begins Phase II of GKT831 in PBC

Genkyotex S.A. (Euronext:GKTX) began a Phase II trial to evaluate once- and twice-daily 400 mg GKT831 (formerly GKT137831) for 24 weeks in 102 patients with primary biliary cholangitis (PBC) and an inadequate response to ursodeoxycholic...
BC Innovations | May 3, 2017
Distillery Therapeutics

Neurology

INDICATION: Depression Mouse studies suggest inhibiting NOX1 could help treat depression. In two mouse models of depression, NOX1 knockdown decreased social avoidance and acute stress-induced immobility compared with normal expression. Next steps could include identifying...
Items per page:
1 - 10 of 33